Back to Browse Journals » Clinical Interventions in Aging » Volume 4

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia

Authors Dhiren Singh, Daniel W O’Connor

Published Date August 2009 Volume 2009:4 Pages 351—355

DOI http://dx.doi.org/10.2147/CIA.S3252

Published 26 August 2009

Dhiren Singh1,2, Daniel W O’Connor1

1Department of Psychological Medicine, Monash University, Melbourne, Australia; 2Peninsula Mental Health Service, Melbourne, Australia

Abstract: Antipsychotic medication is the mainstay of treatment in elderly patients with psychosis. In recent years, second generation antipsychotics have come to be preferred. Longacting risperidone is the first such antipsychotic available for use in this vulnerable group of patients and offers an attractive alternative to traditional medications. The available literature revealed that long-acting risperidone is generally well tolerated and is effective in treating both the positive and negative symptoms of schizophrenia. Despite a lack of randomized trials and head-to-head studies, it appears to be a useful addition to the treatment armory for patients with chronic psychosis who require a depot preparation. Further research into its endocrine and metabolic side effects is needed.

Keywords: risperidone, long-acting injection, old age, efficacy, safety

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies

Kevin J Ruff, Dale P DeVore, Michael D Leu, Mark A Robinson

Clinical Interventions in Aging 2009, 4:235-240

Published Date: 18 May 2009

Restless legs syndrome: differential diagnosis and management with pramipexole

Francesca Brindani, Francesca Vitetta, Franco Gemignani

Clinical Interventions in Aging 2009, 4:305-313

Published Date: 18 June 2009

Dietary habits and cardiovascular disease risk in middle-aged and elderly populations: a review of evidence

Eleni Tourlouki, Antonia-Leda Matalas, Demosthenes B Panagiotakos

Clinical Interventions in Aging 2009, 4:319-330

Published Date: 14 July 2009

Facial rejuvenation for middle-aged women: a combined approach with minimally invasive procedures

Alberto Goldman, Uwe Wollina

Clinical Interventions in Aging 2010, 5:293-299

Published Date: 14 September 2010

Epigenomics in cancer management

Fabricio F Costa

Cancer Management and Research 2010, 2:255-265

Published Date: 27 October 2010

Clinical intervention in aging: ethicolegal issues in assessing risk and benefit

Pierre Mallia

Clinical Interventions in Aging 2010, 5:373-380

Published Date: 2 December 2010

Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure

Donatella Del Sindaco, Maria Denitza Tinti, Luca Monzo, et al

Clinical Interventions in Aging 2010, 5:381-393

Published Date: 3 December 2010

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG

Clinical Ophthalmology 2012, 6:343-363

Published Date: 6 March 2012